Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

Share Price is delayed by 15 minutes
Get Live Data
3,640.00    0.00 (0.00%)
Bid:
3,654.00
Ask:
3,658.00
Spread: 4.00 (0.109%)
Market Cap: £13.75b
HLMA Live PriceLast checked at - London Stock Exchange

Intraday Halma Share Chart

Acquisition

27 Apr 2021 07:00

RNS Number : 6459W
Halma PLC
27 April 2021
 

Halma plc ('Halma' or the 'Group')

Acquisition

Halma, the global group of life-saving technology companies focused on growing a safer, cleaner and healthier future, today announces that it has acquired PeriGen, Inc., ("PeriGen"), based in North Carolina, USA.

PeriGen's advanced technology protects mothers and their unborn babies by alerting doctors, midwives and nurses to potential problems during childbirth. Its software solutions use artificial intelligence to provide an automated early warning platform during labour, enabling healthcare professionals to assess complex data more easily and allowing them to spend more time on direct patient care.

The cash consideration for PeriGen is US$58m (approximately £42m), on a cash and debt free basis, which will be funded from Halma's existing facilities. PeriGen's unaudited revenue for the 12 months to the end of March 2021 was approximately US$20m (approximately £14m), with return on sales slightly above Halma's target range of 18%-22%.

Andrew Williams, Group Chief Executive at Halma, commented:

"We are excited by the opportunities offered by PeriGen's digital technology in helping clinicians protect the health of mothers and babies during childbirth, while achieving better clinical outcomes in the increasing proportion of complex births. PeriGen is highly aligned with our purpose, broadens our presence in patient assessment and monitoring into the US perinatal care market, and further extends our artificial intelligence and analytics capabilities."

For further information, please contact:

Halma plc

Andrew Williams, Group Chief Executive +44 (0)1494 721111

Marc Ronchetti, Chief Financial Officer

Charles King, Head of Investor Relations +44 (0) 7776 685948

Clayton Hirst, Director of Corporate Affairs +44 (0) 7384 796 013

MHP Communications

Andrew Jaques / Giles Robinson +44 (0)20 3128 8788

A copy of this announcement, together with other information about Halma, may be viewed on its website: www.halma.com

 

 

 

About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day.

Its purpose defines the three broad market areas where it operates:

· Safety: protecting life as populations grow and protecting worker safety.

· Environment: improving food and water quality, and monitoring air pollution.

· Health: meeting rising healthcare demand as growing populations age and lifestyles change.

It employs over 7,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

In January 2021, Halma was named Britain's Most Admired Company by Management Today.

Further information on PeriGen

PeriGen's Electronic Fetal Monitoring (EFM) software is used in childbirth to continuously assess fetal heart rate and contraction patterns, maternal vital signs, and labour progress at both the bedside and from central nursing stations. It provides clinical warning signs during labour, including trending alerts to notify clinicians of situations that may require interventions.

PeriGen's Vigilance early warning system is the only FDA cleared, automated and continuous assessment tool for trending maternal and fetal clinical warning signs in childbirth. This analytics solution is powered by an AI machine-learning algorithm that guides doctors and nurses during childbirth.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQIFMPTMTBTBBB
Date   Source Headline
16th Jun 20227:00 amRNSFinal Results
14th Apr 20227:00 amRNSAcquisition
7th Apr 20227:00 amRNSSite Visit
28th Mar 20221:59 pmRNSDirector/PDMR Shareholding
23rd Mar 20227:00 amRNSTrading update
21st Feb 20227:00 amRNSAcquisition
17th Jan 20227:00 amRNS2021 AGM – Voting Results Update Statement
30th Nov 20211:05 pmRNSDirector/PDMR Shareholding
19th Nov 20217:00 amRNSAcquisition
18th Nov 20217:00 amRNSHalf Year Results
15th Nov 20217:00 amRNSDirectorate Change
15th Oct 20211:06 pmRNSDirector/PDMR Shareholding
4th Oct 20212:12 pmRNSDirector/PDMR Shareholding
23rd Sep 20211:01 pmRNSDirector/PDMR Shareholding
22nd Sep 20217:00 amRNSTrading update
9th Sep 202110:22 amRNSDirector Declaration
9th Aug 20217:00 amRNSM&A Update
26th Jul 202111:01 amRNSDirector/PDMR Shareholding
22nd Jul 20213:00 pmRNSResult of AGM
5th Jul 20214:05 pmRNSDirector/PDMR Shareholding
30th Jun 20211:50 pmRNSDirector/PDMR Shareholding
23rd Jun 20214:47 pmRNSAnnual Financial Report
10th Jun 20217:01 amRNSUnaudited restated segmental information
10th Jun 20217:00 amRNSFull Year Results 2021
27th Apr 20217:00 amRNSAcquisition
26th Mar 20217:00 amRNSAppointment of independent non-executive Director
24th Mar 20217:00 amRNSTrading update
23rd Feb 20217:54 amRNSDirector Declaration
10th Feb 20214:52 pmRNSDirector/PDMR Shareholding
9th Feb 20217:00 amRNSDirectorate Change
21st Dec 20202:00 pmRNSAcquisition
18th Dec 20207:00 amRNSDisposal
4th Dec 20207:04 amRNSDirector Declaration
2nd Dec 20204:08 pmRNSDirector/PDMR Shareholding
25th Nov 20203:20 pmRNSDirector/PDMR Shareholding
19th Nov 20207:00 amRNSHALF YEAR RESULTS 2020/21
5th Oct 20201:12 pmRNSDirector/PDMR Shareholding
23rd Sep 20207:05 amRNSDirector Declaration
23rd Sep 20207:00 amRNSChair retirement
23rd Sep 20207:00 amRNSTrading update
4th Sep 20204:57 pmRNSResult of AGM
31st Jul 20204:06 pmRNSDirector/PDMR Shareholding
24th Jul 20205:02 pmRNSAnnual Financial Report
17th Jul 20209:32 amRNSDirector/PDMR Shareholding
14th Jul 20207:00 amRNSFinal Results
15th May 20201:29 pmRNSElectronic Communications with Shareholders
27th Apr 202012:46 pmRNSDisclosure of Rights Attached to Equity Shares
21st Apr 20207:00 amRNSCOVID-19 Update
2nd Apr 20207:05 amRNSExecutive Board changes
19th Mar 20207:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.